SCHEMBL17243646

SCHEMBL17243646

CCn1ccc2cnc3ccsc3c21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 9/20 0.36
ADORA2A P29274 3/20 0.35
ADORA1 P30542 3/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA2B P29275 1/20 0.35
PDE4B Q07343 5/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PDE7B Q9NP56 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
AXL P30530 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
PIK3CD O00329 1/20 0.33
JAK1 P23458 1/20 0.33
TYRO3 Q06418 1/20 0.33
PDE4A P27815 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
PDE3B Q13370 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17243648 0.88 TLR7 (0.34) PDE7AADORA2AADORA1ADORA3ADORA2B
SCHEMBL17243647 0.80 ADORA2A (0.39) ADORA2AADORA1ADORA3ADORA2BL3MBTL1
SCHEMBL20101423 0.76 CDK4 (0.33) PDE7APDE4BL3MBTL1PDE7BMEN1
SCHEMBL8570253 0.67 AXL (0.45) ADORA2AADORA1ADORA3ADORA2BPDE4B
SCHEMBL12761342 0.67 MEN1 (0.58) PDE7APDE4BL3MBTL1PDE7BMEN1
SCHEMBL31359683 0.67 HSP90AA1 (0.36) MEN1KMT2A
SCHEMBL31359719 0.67 MAPT (0.35) ADORA2AMEN1KMT2A
SCHEMBL22796965 0.66 KDM4E (0.43) PDE7APDE4BL3MBTL1PDE7BMEN1
SCHEMBL25258664 0.65 TLR7 (0.47) PDE4BPDE4APDE4CPDE4DPDE3B
SCHEMBL31270557 0.65 TLR7 (0.47) PDE4BPDE4APDE4CPDE4DPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148460-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2018-05-31 US disclosed
US-9908895-B2 Tricyclic fused thiophene derivatives as JAK inhibitors INCYTE CORPORATION (US) 2018-03-06 US disclosed
US-9777017-B2 Tricyclic fused thiophene derivatives as JAK inhibitors INCYTE HOLDINGS CORPORATION (US) 2017-10-03 US disclosed
US-20160024109-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS INCYTE HOLDINGS CORPORATION 2016-01-28 US disclosed
US-20160015695-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2016-01-21 US disclosed
US-9181271-B2 Tricyclic fused thiophene derivatives as JAK inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015695-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 PDE7A 2851/4885ADORA2A 4025/4885ADORA1 4689/4885
US-20180148460-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 PDE7A 2851/4885ADORA2A 4025/4885ADORA1 4689/4885
US-20160024109-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 PDE7A 2851/4885ADORA2A 4025/4885ADORA1 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.